The benefit was maintained beyond the 2-year treatment period.
Throughout the COVID-19 pandemic, clinicians who care for patients with lung cancer have made multiple treatment approach changes for this vulnerable population.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
A retrospective study found that a radiomic-clinicopathologic nomogram performed better than other tools in predicting biochemical recurrence-free survival after surgery for prostate cancer.
A recent wave of approvals has transformed the treatment landscape in non-small cell lung cancer with the most common EGFR mutations— EGFR exon 19 or exon 21 L858R- substitution mutations—giving clinicians a choice between 6 different interventions in the metastatic setting.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
A comprehensive analysis of advanced kidney cancer tumors from the IMmotion151 trial provided new insights on the tumor features that underpin responses to therapy.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
A new study suggests that radiation prior to CAR-T infusion is a safe bridging therapy — and this approach may even decrease some of the immunotherapy’s side effects, researchers hypothesize.
